<DOC>
	<DOCNO>NCT00179413</DOCNO>
	<brief_summary>In study Peg-Intron test see give good result Colchicine . At time , currently recommend maintenance treatment patient fail respond Interferon/Rebetron/Peg Intron advance fibrosis . The purpose study compare two treatment slow progression liver disease prevent liver failure liver cancer . The treatment cure Hepatitis C , evaluate see slow disease progression .</brief_summary>
	<brief_title>Study Long-Term Peg Intron Vs. Colchicine Non-Responders .</brief_title>
	<detailed_description>We propose randomize trial Peg-Intron 0.5mcg per kg weekly versus colchicine 0.6mg bid prior non-responders Interferon , Rebetron , PegIntron , PegIntron &amp; Ribavirin third agent Pegasys , CellCept , Amantadine advance fibrosis/cirrhosis . The specific aim proposal evaluate role long term Peg-Intron therapy natural history patient advance chronic HCV infection primary focus prevention hepatic decompensation , progression fibrosis hepatoma development . The study design focus 3 monthly clinical evaluation decompensation liver function , rigorous clinical screening development hepatocellular cancer liver biopsy determination progression liver fibrosis every second year .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>*Adult male female , age 18 75 year HCV RNA positive PCR Previous treatment least three month interferon interferon / Ribavirin . Patients interferon least 2 month prior enrollment . 1 . Nonresponders identified failure clear virus PCR minimum 3month course treatment treatment least 2 month positive PCR HCV prior entry current study , 2 ) Partial responder reduction 1 long HCV RNA , virus still detectable , 3 ) Breakthrough patient negative treatment , virus appear still treatment , 4 ) Relapsers define negative PCR point treatment , virus reoccurred detectable HCV PCR treatment stop . Patients liver biopsy show least Stage 3 disease prior consider study . A baseline liver biopsy necessary inclusion study . Baseline liver biopsy perform within six month enter study . In patient cirrhosis endoscopic evidence portal hypertension , biopsy within last 2 year acceptable baseline biopsy . For patient establish cirrhosis liver biopsy portal hypertension , biopsy within 12 month use baseline biopsy available evaluation Pathology core . All patient still require liver biopsy 2 year 4 year . The decision biopsy 2 4 year also clinical decision presence clinical progression coagulopathy , may risk liver biopsy , Investigator call PI , Dr. Afdhal waiver biopsy . Patients Ishak Stage 3 4 require biopsy within 6 month randomization . Hemoglobin &gt; = 11 g/dl male 10 g/dl female Neutrophil count &gt; 1,500/mm3 Platelets &gt; 50 , 000/mm3 Platelet count : For standard dose PEGIntron 0.5mcg/kg platelet count must great 70,000 . Patients platelet count 50 70,000 start 0.25mcg/kg week 0 4 . If platelet fall less 30,000 , stop treatment . If platelet remain &gt; 50,000 week 4 , PEGIntron increase 0.5mcg/kg . Patients randomized Colchicine platelets 50,000 70,000 started standard dose 0.6mg bid po standard dose reduction . Prothrombin time &lt; = 3secs prolonged compare control equivalent INR &lt; 1.5 Total bilirubin &lt; 3gm/dL Fasting blood sugar &lt; = 115 mg/dl within 20 % upper limit normal nondiabetic patient Albumin ( &gt; 2.8mg/dl ) Serum creatinine &lt; 1.4 mg/dL TSH within normal range ( Patients thyroid disease well control eligible remainder inclusion/exclusion criterion meet ) HIV negative . HBsAg negative Childs Pugh score less equal 7 Serum positive antihepatitis C antibodies HCV RNA . Alphafetoprotein &lt; 100ng/ml ultrasound negative focal mass HCC . For patient Alphafetoprotein &gt; 100 ng/ml either triple phase contrast CT scan MRI gadolinium must show focal mass evidence HCC Ultrasound evidence focal mass suggestive hepatoma ( within 6 month inform consent ) . Documentation sexually active female patient childbearing potential practicing adequate contraception treatment period . A urine pregnancy test obtain entry prior initiation treatment must negative . Female patient must breastfeed . Documentation sexually active male patient practice acceptable method contraception treatment period . Written inform consent specific protocol obtain prior entry . Any cause liver disease base patient history biopsy ( applicable ) chronic hepatitis C include limited : Coinfection hepatitis B HIV Hemochromatosis ( confirm genetic testing ) Alpha1 antitrypsin deficiency Wilson 's disease Renal liver transplant patient Autoimmune hepatitis Alcoholic liver disease Obesity induce liver disease Drug relate liver disease In addition : Evidence decompensated liver disease history presence ascites , spontaneous encephalopathy . Patients past bleed esophageal varix bleed 1 year include . Hypersensitivity alpha interferon Drug relate liver disease Hemoglobinopathies ( e.g . Thalassaemia , sickle cell disease ) . Patients clinically significant retinal abnormality . Substance abuse , alcohol ( Â· &gt; 80 gm/day ) , I.V . drug inhale drug . If patient history substance abuse , consider inclusion protocol , patient must abstain use abused substance least 6 month . Patients methadone allow study restriction standard care HCV therapy . Patients history organ transplantation exclude . Preexisting psychiatric condition , especially depression , history severe psychiatric disorder , major psychosis , suicidal ideation and/or suicidal attempt exclude . Patients history mild depression may enter protocol meet follow eligibility criterion monitor intensively . Mild depression : include either situational depression limit period depressive symptom , significantly interfere patient 's work daily function . Any patient active manic element his/her previous symptom complex exclude . Any known preexisting medical condition could interfere patient 's participation completion study : Preexisting psychiatric condition , especially severe depression , history severe psychiatric disorder CNS trauma seizure disorder require therapy Significant cardiac dysfunction previous 6 month e.g . angina , CCF , hypertension arrhythmia Patients treatment eligible long symptom free previous 6 month . Poorly control diabetes mellitus Chronic pulmonary disease ( e.g . COAD ) Immunologically mediate disease ( e.g . inflammatory bowel disease , SLE , ITP , autoimmune hemolytic anemia , scleroderma , rheumatoid arthritis , severe psoriasis ) Clinical gout Patients clinically significant retinal abnormality Patients organ transplant Any condition , view investigator , would make patient unsuitable enrolment , could interfere patient participate complete protocol include well .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>interferon</keyword>
	<keyword>colchicine</keyword>
</DOC>